In case of DNMT3A and DNMT3B, they were found out to be overexpressed in AML patients but their expression levels were not positively correlated with blood cancer stage nor poor prognosis of AML patients (Supplementary Fig. 8a–h). This evidence concerns the gene DNMT3B and hematopoietic and lymphoid system neoplasm.